Navigation Links
FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
Date:3/11/2008

increasing the half-life of native GLP-1. DPP-4 is a validated target for the treatment of Type II diabetes and inhibitors of DPP-4 have been shown to lower post-prandial glucose and HbA1c levels. Diabetes is a major healthcare problem throughout the world with the prevalence of the disease projected to double to 360 million cases worldwide by the year 2030 according to the World Health Organization.(2)

Certain statements in this press release, including statements regarding the Company's research and development effort, the Company's expectation to initiate human clinical studies, the Company's ability to finance its development programs into human clinical testing, and the Company's ability to successfully capitalize on the early stage research are subject to risks and uncertainties. These risks and uncertainties include risks and uncertainties related to: our ability to discover and develop new compounds and products using a novel approach to drug discovery; the early stage of all of our discovery and development efforts; our ability to complete preclinical and clinical development of our products; our ability to obtain and maintain regulatory approvals for our products; competition from other technologies and technologies similar to ours; obtaining, maintaining and protecting intellectual property utilized by our products; changes in legislation and regulations affecting our products and potential product candidates; our need to obtain additional funding to support our business activities; our dependence on collaborators and other third parties for development, manufacture, marketing, sales and distribution of products; the ability of our licensees to achieve developmental, regulatory and other milestones and to commercialize their products; the effect of conditions in the pharmaceutical industry and the economy in general, as well as certain other risks and uncertainties.

References:

(1) American Diabetes Association Web site. Available at:
'/>"/>

SOURCE Arisaph Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
6. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
7. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
11. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- Xencor, Inc. (NASDAQ: XNCR ), a clinical-stage biopharmaceutical ... autoimmune diseases, asthma and allergic diseases, and cancer, today ... to its board of directors. "Yujiro,s ... a tremendous asset to our board," said Bassil ... Xencor. "Xencor faces a range of opportunities for our ...
(Date:7/30/2015)... 30, 2015  ResMed (NYSE: RMD ... definitive agreement to acquire Curative Medical, a ... sleep-disordered breathing medical devices and accessories. ... with ResMed,s global leadership in sleep and respiratory medicine, ... China suffering from sleep-disordered breathing ...
(Date:7/30/2015)... we bring you a special edition of #MedicareMonday on Medicare,s 50 th anniversary. ... Medicare resources and continue highlighting the success of the prescription drug benefit, commonly referred ... out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
Breaking Medicine Technology:Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
... -- URINOZINC® Prostate Formula Added to GNC Live ... The original, patented, URINOZINC® Prostate Formula ... Well stores and at select GNC franchise stores. ... stores spread over 49 countries worldwide. URINOZINC® is ...
... LONDON, June 14, 2011 MGT Capital Investments, Inc. (NYSE ... 8, 2011 it received notice from the NYSE Amex (the ... following Exchange continued listing standards:  Section 1003(a)(i) of the Company ... less than $2,000,000 and losses from continuing operations and/or net ...
Cached Medicine Technology:Patented URINOZINC® Prostate Formula Now Available at GNC Stores 2Patented URINOZINC® Prostate Formula Now Available at GNC Stores 3MGT Capital Investments Receives NYSE Amex Listing Deficiency Notification 2MGT Capital Investments Receives NYSE Amex Listing Deficiency Notification 3
(Date:8/1/2015)... ... August 01, 2015 , ... The condition where veins are enlarged ... women often causing pain and discomfort. Those who spend a lot of time on ... Houston Vein Center is doing what it can to create awareness and provide a ...
(Date:8/1/2015)... ME (PRWEB) , ... August 01, 2015 , ... Tina ... Retail Champions.” , Wilcoxson was given that honor by the National Retail Federation, the ... retail industry. Wilcoxson was one of three Maine business owners to be named as ...
(Date:8/1/2015)... ... August 01, 2015 , ... ... L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & Wellness (“Premier”) — ... portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical Therapy & Wellness ...
(Date:8/1/2015)... ... August 01, 2015 , ... Lume Wellness creators Alex, Robert, and Sam have ... the Apple AppStore. , The app is designed to track various metrics of ... tool to view personal health and use this information for positive behavior modification. Lume ...
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was featured ... latest and coolest applications on the market for iOS, Android, and Windows. Joe Toohey, ... viewers allows users to clarify, edit and delete any message including ones already sent. ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Local Retail Advocate Wins National Recognition 2Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2
... the Moores UCSD Cancer Center and the Arizona Oncology Services ... the Strut-Adjusted Volume Implant (SAVI) controls the rate of cancer ... brachytherapy. This study also demonstrates the accuracy and flexibility of ... and minimize the exposure of healthy surrounding tissue and organs. ...
... N.J. (July 12, 2010) A new study by ... University Medical Center sheds light on how bortezomib (VELCADE), ... known as proteasome inhibitors, works in mantle cell lymphoma. ... might benefit most from bortezomib. Additionally, researchers demonstrate that ...
... 2010 In an effort that will contribute ... Philippines and surrounding regions, the Laboratory Services Division ... (FDA) has attained the internationally recognized accreditation for ... International Electrotechnical Commission (ISO/IEC) 17025:2005. The FDA celebrates ...
... LANSING, Mich., July 12, 2010 Drinking tart cherry juice ... spent awake after going to sleep, according to a new ... 1 . A team of University of Pennsylvania, University ... pilot study on the sleep habits of 15 older adults. ...
... Starting in February 2011, Springer will publish a new ... . Focusing exclusively on translational aspects of drug ... for publication of high-quality research. It is an ... Drug Delivery and Translational Research will publish ...
... Mass. -- A subtle mutation affecting the epigenome - a ... lead to an inherited form of mental retardation that affects ... also involves cleft lip or cleft palate, appears to hinge ... offer several potential drug targets. The study, published online ...
Cached Medicine News:Health News:Radiation device allows for targeted breast radiation to control cancer 2Health News:Study makes exciting progress in elucidating the mechanisms of bortezomib in lymphoma 2Health News:Study makes exciting progress in elucidating the mechanisms of bortezomib in lymphoma 3Health News:Study makes exciting progress in elucidating the mechanisms of bortezomib in lymphoma 4Health News:Medicine quality in Philippines and region strengthened with Philippine FDA's accreditation 2Health News:New study suggests tart cherry juice can be a natural solution for insomnia 2Health News:Springer launches Drug Delivery and Translational Research 2Health News:Study implicates new epigenetic player in mental retardation and facial birth defects 2Health News:Study implicates new epigenetic player in mental retardation and facial birth defects 3
The new TOPCON 8800 Series of auto refractors and auto kerato-refractors satisfies the needs of today's demanding eyecare practice !...
The perfect tool to prepare for in-service or licensing exams, for recertification, or for use as a clinical refresher....
... TruFlow™ Oxygen flowmeter with a Lexan®inner calibrated ... calibration and manufacturing defects. A wide range ... needs. Also available with all popular inlet ... and double unit configurations. Our extra large ...
... Oxygen flowmeter with a Lexan®inner calibrated flow ... and manufacturing defects. A wide range of ... Also available with all popular inlet connections, ... double unit configurations. Our extra large knob ...
Medicine Products: